Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BHQ880 with bortezomib and dexamethasone in untreated multiple myeloma with renal impairment
2009-010875-26Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing BHQ880 + bortezomib + dexamethasone with Placebo + bortezomib + dexamethasone (2 arms). Primary endpoint: Time to first skeletal-related event. Started Jun 2011; status: completed.
02
Drugs
BHQ880
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-010875-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010875-26.